Clinical Trial Update: Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia. [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating whether adding budesonide to poractant alfa reduces bronchopulmonary dysplasia in premature infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia
• Respiratory Distress Syndrome

Drugs mentioned

• Budesonide (BUDESONIDE)
• Poractant alfa (poractant alfa)

Snippet

Sponsor: Hospital Central "Dr. Ignacio Morones Prieto" | Conditions: Bronchopulmonary Dysplasia, Infant,Premature | Phase 4 | Status: UNKNOWN